This company listing is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Destiny Pharma Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Destiny Pharma's earnings have been declining at an average annual rate of -4.9%, while the Biotechs industry saw earnings growing at 11.8% annually. Revenues have been growing at an average rate of 51.3% per year.
Belangrijke informatie
-4.9%
Groei van de winst
10.0%
Groei van de winst per aandeel
Biotechs Groei van de industrie | -14.6% |
Inkomstengroei | 51.3% |
Rendement op eigen vermogen | -61.6% |
Nettomarge | -680.3% |
Laatste winstupdate | 31 Dec 2023 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Destiny Pharma geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
31 Dec 23 | 1 | -6 | 8 | 0 |
30 Sep 23 | 1 | -6 | 8 | 0 |
30 Jun 23 | 1 | -6 | 8 | 0 |
31 Mar 23 | 1 | -6 | 8 | 0 |
31 Dec 22 | 0 | -7 | 8 | 0 |
30 Sep 22 | 0 | -6 | 8 | 0 |
30 Jun 22 | 0 | -6 | 7 | 0 |
31 Mar 22 | 0 | -6 | 7 | 0 |
31 Dec 21 | 0 | -5 | 6 | 0 |
30 Sep 21 | 0 | -5 | 7 | 0 |
30 Jun 21 | 0 | -5 | 7 | 0 |
31 Mar 21 | 0 | -5 | 7 | 0 |
31 Dec 20 | 0 | -5 | 7 | 0 |
30 Sep 20 | 0 | -5 | 6 | 0 |
30 Jun 20 | 0 | -5 | 6 | 0 |
31 Mar 20 | 0 | -5 | 6 | 0 |
31 Dec 19 | 0 | -5 | 6 | 0 |
30 Sep 19 | 0 | -5 | 6 | 0 |
30 Jun 19 | 0 | -5 | 6 | 0 |
31 Mar 19 | 0 | -5 | 6 | 0 |
31 Dec 18 | 0 | -5 | 6 | 0 |
30 Sep 18 | 0 | -5 | 5 | 0 |
30 Jun 18 | 0 | -4 | 4 | 0 |
31 Mar 18 | 0 | -4 | 4 | 0 |
31 Dec 17 | 0 | -3 | 3 | 0 |
30 Sep 17 | 0 | -2 | 2 | 0 |
30 Jun 17 | 0 | -2 | 2 | 0 |
31 Mar 17 | 0 | -1 | 2 | 0 |
31 Dec 16 | 0 | -1 | 1 | 0 |
31 Dec 15 | 0 | -1 | 1 | 0 |
31 Dec 14 | 0 | -2 | 2 | 0 |
Kwaliteitswinsten: D89 is currently unprofitable.
Groeiende winstmarge: D89 is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: D89 is unprofitable, and losses have increased over the past 5 years at a rate of 4.9% per year.
Versnelling van de groei: Unable to compare D89's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: D89 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (2.8%).
Rendement op eigen vermogen
Hoge ROE: D89 has a negative Return on Equity (-61.56%), as it is currently unprofitable.